Baiyang Medical (301015.SZ): Currently has established a presence in the high-end medical instrument field with Atricure's atrial fibrillation treatment devices, and products like the full magnetic suspension artificial heart from Tongxin Medical.

HealthTimes reported on November 28th that Baiyang Pharmaceuticals (301015.SZ) stated in a recent investor relations event that the company has currently laid out Atricure's atrial fibrillation treatment equipment, Syncardia's fully magnetically levitated artificial heart, Medisense's ultrasound-guided electromagnetic positioning puncture device, and Wecare's home ECG monitor in the high-end medical instruments field; recently, the company has obtained the exclusive commercial operation rights of ZAP Surgical's ZAP-X Mars Rover radiotherapy surgical robot in mainland China and Hong Kong-Macao region.

Gelonghui FinanceNov 28 04:29 ET

AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

BusinesswireNov 20 08:00 ET

The Market Lifts AtriCure, Inc. (NASDAQ:ATRC) Shares 28% But It Can Do More

Simply Wall StNov 6 06:00 ET

US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results

Yahoo FinanceNov 1 07:51 ET

Are Investors Undervaluing AtriCure, Inc. (NASDAQ:ATRC) By 29%?

Simply Wall StOct 31 08:47 ET

AtriCure | 10-Q: Q3 2024 Earnings Report

SECOct 30 11:52 ET · Announcements